Celgene Corporation; Rule 14a-8 no-action letter

First Page		Document Content
Date: 2015-02-06 09:08:34 United States securities law Proxy statement Statements Celgene Direct lobbying in the United States Lobbying American Federation of State County and Municipal Employees Securities Exchange Act Lenalidomide SEC filings Lobbying in the United States Immunosuppressants		Celgene Corporation; Rule 14a-8 no-action letter Add to Reading List Source URL: www.sec.gov Download Document from Source Website File Size: 2,33 MB Share Document on Facebook

	UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release NoMarch 13, 2018 ACCOUNTING AND AUDITING ENFORCEMENT DocID: 1vq0h - View Document
	CONFLICT MINERALS The following is provided in connection with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Securities and Exchange Commission Rule 13p-1 and Form SD (17 CFR 240.13p-1 DocID: 1vnAy - View Document
	April 07, 2017 SEC SHUTS DOWN BOILER ROOM OPERATIONS IN CAVITE The Securities and Exchange Commission (SEC) in coordination with the National Bureau of Investigation (NBI) apprehended several persons caught in the act o DocID: 1v13k - View Document
	UNITED STATES OF AMERICA before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release NoMay 29, 2018 DocID: 1ur6n - View Document
	UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release NoDecember 18, 2017 The Securities and Exchange Commission (“Commission”) announced the temp DocID: 1uiZb - View Document